Photo by Dalle-E OpenAI

Cassava Sciences to Present at Jefferies Biotech CNS/Neuro Summit

Cassava Sciences, a leading biotechnology company focused on the treatment of Alzheimer’s disease dementia, has announced that its President & CEO, Remi Barbier, has been invited to present at the prestigious Jefferies Biotech CNS/Neuro Summit. The event is scheduled to take place in New York on Wednesday, October 11, 2023, at 10:30am ET.

The presentation by Cassava Sciences will provide valuable insights into the company’s mission to detect and treat neurodegenerative diseases, with a specific focus on Alzheimer’s disease. The company’s lead drug candidate, oral simufilam, is currently being evaluated in two global Phase 3 clinical studies for Alzheimer’s disease dementia.

The live webcast of the presentation will be available for those unable to attend in person, and an archived replay will also be accessible for later viewing. Interested individuals can access the live webcast at, while the archived replay can be found on Cassava Sciences’ official website at

In addition to Remi Barbier’s presentation, Eric Schoen, the Chief Financial Officer of Cassava Sciences, will be attending the JonesTrading 2023 Healthcare Summit in Miami on October 10-11th. This event will provide an opportunity for networking and further discussions related to the company’s advancements in the field of neurodegenerative disease treatment.

Cassava Sciences, headquartered in Austin, Texas, is committed to making significant contributions to the field of Alzheimer’s disease research. By stabilizing a critical protein in the brain, the company’s novel science aims to address the underlying causes of the disease. It is important to note that Cassava Sciences’ product candidates have not yet been approved by any regulatory authority, and their safety and efficacy in humans are yet to be established.

For more information about Cassava Sciences and its groundbreaking research, please visit their official website at For any inquiries, please contact Eric Schoen, the Chief Financial Officer, at (512) 501-2450 or via email at

Leave a comment